Takeaway

• Adding ¹⁷⁷ Lu-PSMA-617 to standard of care (SOC) in patients with metastatic castration-resistant prostate cancer (mCRPC) after androgen receptor pathway inhibition and chemotherapy extended overall survival (OS) and delayed radiographic progression-free survival (rPFS).

Why this matters

• Despite recent therapeutic advances, mCRPC remains invariably fatal.
• Prostate-specific membrane antigen (PSMA) is...